Article

Antibacterial Activity of Electrospun Polyacrylonitrile Copper Nanoparticle Nanofibers on Antibiotic Resistant Pathogens and Methicillin Resistant Staphylococcus aureus (MRSA)

William B. Wang * and Jude C. Clapper

Upper School, Taipei American School, 800 Chung Shan North Road, Section 6, Taipei 11152, Taiwan; jclapper@tas.tw
* Correspondence: williamwang178243@gmail.com

Abstract: Bacteria induced diseases such as community-acquired pneumonia (CAP) are easily transmitted through respiratory droplets expelled from a person’s nose or mouth. It has become increasingly important for researchers to discover materials that can be implemented in vitro surface contact settings which disrupt bacterial growth and transmission. Copper (Cu) is known to have antibacterial properties and have been used in medical applications. This study investigates the antibacterial properties of polyacrylonitrile (PAN) based nanofibers coated with different concentrations of copper nanoparticles (CuNPs). Different concentrations of copper sulfate (CuSO₄) and polyacrylonitrile (PAN) were mixed with dimethylformamide (DMF) solution, an electrospinning solvent that also acts as a reducing agent for CuSO₄, which forms CuNPs and Cu ions. The resulting colloidal solutions were electrospun into nanofibers, which were then characterized using various analysis techniques. Methicillin-Resistant isolates of Staphylococcus aureus, an infective strain that induces pneumonia, were incubated with cutouts of various nanocomposites using disk diffusion methods on Luria-Bertani (LB) agar to test for the polymers’ antibacterial properties. Herein, we disclose that PAN-CuNP nanofibers have successfully demonstrated antibacterial activity against bacteria that were otherwise resistant to highly effective antibiotics. Our findings reveal that PAN-CuNP nanofibers have the potential to be used on contact surfaces that are at risk of contracting bacterial infections, such as masks, in vivo implants, or surgical intubation.

Keywords: copper; nanoparticles; polyacrylonitrile; electrospinning; Methicillin-Resistant Staphylococcus aureus; antibacterial activity

1. Introduction

Airborne diseases are easily transmitted through respiratory droplets expelled from a person’s nose or mouth [1–6]. Recently, human beings have suffered from negative clinical outcomes due to the rapid transmission and high infectivity of these diseases [7,8]. Transmitters frequently excrete bacteria-containing microscale aerosol particles. Since these particles are extremely lightweight, they can easily disperse between carriers via air current diffusion [9,10]. Therefore, it has become increasingly important for researchers to discover materials that disturb or interrupt airborne bacterial transmission.

A prime example of an airborne bacterial disease is pneumonia, which is a common cause of health complications and death around the world [11–13]. Due to its high transmission rate, patients suffering from community-acquired pneumonia (CAP) develop acute lung infections caused by deposits of bacteria-containing aerosol particles in their alveoli [14–18]. The alveoli of infected individuals become filled with pus and fluid from tissue debris and dead blood cells [19–21]. It is common for patients to have trouble breathing due to limited oxygen intake and the inflammation or irritation of their lungs, eventually succumbing from asphyxiation [15,22–24].
One such common pathogen that causes CAP is *Staphylococcus aureus* (*S. aureus*) [25,26]. *S. aureus* is a gram-positive cocci bacteria that can travel through airborne pathways and into respiratory systems, causing patients to experience complications related to pneumonia [27,28]. Professionals in the medical and animal husbandry industries frequently use conventional antibiotics to counter bacteria like *S. aureus*, but over reliance on antibiotics usually results in bacterial mutation [29]. Recent increases in CAP morbidity have been attributed to the rapid spread of Methicillin-Resistant *S. aureus* (MRSA) bacteria strains, which have proven to be insusceptible to conventional antibiotic therapy [30–32]. The most common drug treatment for severe community-acquired MRSA (CA-MRSA) infections is vancomycin, but despite its success in neutralizing MRSA, Vancomycin Intermediate *S. aureus* (VISA) mutation strains have been discovered [33].

CAP-causing microbes tend to remain on high contact surfaces for extended periods of time if they are not eliminated [34–37]. It is common for community acquired diseases, especially lung infections like CAP caused by *S. aureus* variations, to reside atop high contact surfaces such as masks, handles, or clothing [38–40]. Hence, antimicrobial agents should be implemented onto these surfaces to exterminate harmful bacteria before they infect people. However, conventional antibiotics cannot be placed onto high contact surfaces because most antibiotics are used in vivo via direct injection or consumption through the use of pellets or tablets that contain antibiotics; in vitro surface antibiotics are relatively rare [41]. While conventional antibiotics are effective preventative measures set in place to kill disease-inducing pathogens once they enter the body, solid antimicrobial agents such as antimicrobial coatings or nanofibers should be developed to effectively counter CAP-causing microbes the moment they come into contact with patients or transmitters [42–45].

Carbon-based polymer nanofibers are commonly used in surface engineering applications due to their high surface area to volume ratio, malleability, and compact structure [46,47]. Among various organic carbon polymers, polyacrylonitrile (PAN) could be widely adopted for antimicrobial filtration due to effective fibril formation via electrospinning [48–52]. PAN has unique thermal stability properties that allows it to degrade before reaching its melting point [53–55]. Moreover, PAN is known for its strong mechanical characteristics and high carbon yield, making it the ideal substance for building a long lasting, solvent resistant antibacterial filter [56]. Metals such as gold, copper, and silver have been used in the past in fields such as medicine and environmental science as antimicrobial agents [57]. Copper (Cu) is an extremely accessible and relatively cheap material that is known to have antimicrobial properties and is also nontoxic to humans when consumed at low levels [58–61]. Moreover, Cu has a strong fixation stability on PAN; other studies have also indicated that Cu leaching in water from carbon nanofibers is often negligible [48]. By synthesizing copper nanoparticles (CuNPs) onto carbon-based nanofibers, CuNPs and its subsequent Cu ions formed during the reduction of CuSO$_4$ via *N,N*-Dimethylformamide (DMF) can easily permeate into bacteria [62–64]. Previous studies indicate that DMF, a common reagent and solvent used in colloidal synthesis, reduces Cu$^{2+}$ to atomic CuNPs, which, as seen in X-ray Photoelectron Spectroscopy (XPS) tests shown in Figure S10 and Table S1, could then be later oxidized if it comes into contact with air [65,66]. Due to its high oxidation potential, DMF has the capability of reducing metal salts and forming nanoparticles during colloidal solution formation [67]. When synthesized into nanomaterials via reduction and electrospinning, CuNPs undergo significant physicochemical changes that allows them to have better permeability in pathogens than their bulk counterparts due to their size-dependent crystalline structure and high surface area-to-volume ratio [68]. The electrostatic interactions between the positively charged copper ions and the negatively charged peptidoglycan-based bacteria cell wall ruptures the cell wall via depolarization and releases internal cell contents [62,69]. Biochemical processes inside the cell are also disrupted when Cu ions originating from CuNPs interact with sulfur (S) containing biomolecules, replacing their respective H$^+$ groups and in turn disrupting their molecular structure [62,70]. Moreover, CuNPs and their corresponding ions create reactive oxygen species (ROSs) when interacting with bacteria, which depletes intracellular ATP
production and disrupts DNA replication [62,71]. All of these antibacterial processes result in the subsequent death and degradation of the targeted pathogen (Figure 1).

Electrospinning techniques are often used to synthesize carbon-based polymer nanofibers coated with nanoparticles [72]. DMF can be used as an electrospinning solvent for PAN and a reducing agent for CuSO₄, which induces the chemical formation of CuNPs [73]. The electrospinner ejects PAN/DMF/CuNP solution from a nozzle and uses a high voltage electric field gradient to spin, solidify, and coagulate the solution into a solid PAN-CuNP nanofiber filament (Figure 2) [74].

2. Materials and Methods

2.1. Preparation of PAN/DMF/CuNP Solution

Prior to synthesizing CuNP-coated PAN nanofibers with an electrospinning, different colloidal electrospinning solutions were prepared. Four distinct PAN solutions were prepared by dissolving 10 wt.% of PAN (Merck Co., Ltd., Sigma-Aldrich Company, Neihu, Taipei, Taiwan) in 50 mL DMF (Merck Co., Ltd.). Different percentages (5%, 10%, and 15%...
wt.% w.r.t to weight of PAN) of CuSO$_4$ (Merck Co., Ltd.) were simultaneously dissolved in three of the solutions, with the fourth solution being left as a pure PAN-based control that will not contain CuNPs. The solutions were then stirred using a 50 mm × 8 mm magnetic stir bar (Merck Co., Ltd.) at 200 rpm for 24 h. After the chemicals have homogenized and completely dissolved, a color change from light blue to dark green can be observed (Figure S11), qualitatively screening for and signifying the formation, oxidation, and agglomeration of CuNPs in solution [75].

2.2. Electrospinning

5 mL of PAN/DMF/CuNP solution created a specific concentration of CuSO$_4$ (0%, 5%, 10%, and 15% wt.% w.r.t to weight of PAN) was loaded into a 10 mL single use Luer Slip Syringe (Terumo Co., Ltd., Shibuya City, Tokyo, Japan). The syringe was then affixed to a syringe pump (Inovenso Co., Ltd., Istanbul, Turkey) and connected to an Inovenso Basic System electrosinker (Inovenso Co., Ltd.) via a single use plastic tube that is attached to an electrosinking nozzle (Inovenso Co., Ltd.). A 200 × 200 mm$^2$ piece of aluminum foil was attached onto the movable collection platform of the electrosinker, which was locked in a position 100 mm away from the electrosinking nozzle. The negative electrode clip was then attached to the aluminum foil to allow for the creation of an electric field during the electrosinking process.

The electrosinker was set to operate at a voltage of 30 kV, and the injection rate was adjusted to 2.5 mL/h. Electrosinking concluded once the precursor solution was completely used up and spun into PAN nanofibers.

2.3. Bacterial Culture Preparation and Serial Dilution

Bacteria media and growth plates were prepared prior to growing various bacteria strains. 2.5% wt.% Luria-Bertani (LB) powder (Merck Co., Ltd.) was dissolved in distilled water and sterilized using an autoclave to create the growth media for all bacteria cultures used in this study. Similarly, 2.5% wt.% Luria-Bertani (LB) powder and 1.5% wt.% agar powder (Merck Co., Ltd.) was dissolved in distilled water, sterilized in an autoclave, and evenly poured into 100 × 15 mm polystyrene petri dishes (Alpha Plus Scientific Co., Ltd., Longtan District, Taoyuan City, Taiwan). LB-agar nutrient plates were formed after the solution solidified in the petri dishes.

Cultures of MRSA, MRSA Staphylococcal Cassette Chromosome mec (SCCmec) type II, MRSA SCCmec type III, MRSA SCCmec type IV, MRSA SCCmec type V, VISA, S. aureus, S. epidermidis, S. agalactiae, S. pneumoniae, E. faecalis, K. pneumoniae, and E. coli (Bioresource Collection and Research Center, Hsinchu, Taiwan) were then grown in 2.5% LB broth in a shaking incubator (Thermo Fisher Scientific, Waltham, MA, USA) set at 37 °C and 200 rpm for 24 h. The cultures were then diluted to a 0.5 MacFarland bacterial turbidity standard with a UV-VIS optical density spectrophotometer (Vernier Software & Technology, Beaverton, OR, USA), which provides an optical density comparable to the density of a bacterial suspension with a 1.5 × 10$^8$ colony forming units (CFU/mL). 50 µL of different bacteria was added to each plate and glass beads (Merck Co., Ltd.) were used to equally distribute the bacteria on the plate.

2.4. Zone of Inhibition Antibacterial Tests

A 6.5 mm diameter hole puncher (Long Jer Precise Industry Co., Ltd., Taichung, Taiwan) was used to cut out all nanofiber and control disks. Three fiber disks of diameter 6.5 mm for each of the four concentrations (0%, 5%, 10%, and 15% wt.% w.r.t to weight of PAN) of PAN-CuNP nanofiber was placed onto a LB-agar plate for every bacteria strain. Three pure bulk copper disks of the same diameter were also cut out from a piece of pure copper foil and were used in Zone of Inhibition (ZOI) antibacterial tests under the same conditions for all bacteria strains.

The plates were then incubated with the fiber disks at 37 °C for 24 h in a non-shaking incubator (Deng Yng Co., Ltd., Taishan District, Taipei, Taiwan). After incubation, the
inhibition diameter of the various fiber and control disks were measured with ImageJ (Wayne Rasband, National Institutes of Health, Bethesda, MD, USA), a Java-based image processing program commonly used to analyze ZOI tests.

2.5. PAN-CuNP Nanofiber Characterization Techniques

3D topographical images of the fibers were obtained by using a XE7 Atomic Force Microscope (AFM) (Park Systems, Suwon-si, Korea) to identify the surface morphology of the fibers and the CuNPs coated on them. The AFM images were analyzed using the XEI imaging software (Park Systems), a Java-based image processing program exclusively designed for XE Atomic Force Microscopy.

A Phenom ProX G6 Desktop Scanning Electron Microscope (SEM) (Thermo Fisher Scientific) was used in the study to determine fiber morphology and thickness. Energy Dispersive X-ray (EDX) elemental analysis was also conducted in the SEM to analyze the elemental contents of the nanofibers.

The size of CuNPs that were suspended in PAN-DMF colloidal solution were measured with length characterization tools with a Talos F200X G2 Transmission Electron Microscope (TEM) (Thermo Fisher Scientific). 15% PAN/DMF/CuNP colloidal solution was coated onto a copper grid at a thickness of 100 nm and analyzed with TEM techniques. EDX elemental analysis was conducted in the TEM to analyze the elemental contents of the nanoparticles in the colloidal solution. In addition, dynamic light scattering (DLS) (Beckman Coulter, Inc., Brea, CA, USA) was also used to determine the size distribution of CuNPs suspended in PAN-DMF solution. 1 mL of 15% PAN/DMF/CuNP colloidal solution was loaded into different 12 mm square polystyrene cuvettes (Alpha Plus Scientific Co., Ltd.) and the samples were analyzed with a 4 mW He–Ne laser (Beckman Coulter, Inc.) operating at 633 nm with a scattering angle of 173° on a N5 Submicrometer Particle Size Analyzer.

3. Results

3.1. Morphology Analysis of PAN-CuNP Nanofibers with AFM

The AFM is a powerful non-optical imaging technique used for surface analysis [76]. Pure PAN nanofiber disks and PAN-CuNPs nanofiber disks were analyzed using an AFM to determine their topographical structure. Both images were obtained in a 2500 µm² frame with a non-etching AFM cantilever at a Scan Rate of 0.5 Hz (Figure 3).

Figure 3. (a) 3D AFM Scanning Image of Pure PAN Nanofiber Disk (b) 3D AFM Scanning Image of 15% PAN-CuNP Nanofiber Disk, where Circled Portions Show Evidence of Nanoparticle Formation.

PAN nanofibers have a compact structure, as they were found to scaffold atop each other and frequently intersect. As shown in Figure 3a, nanoparticles were not visible on pure PAN nanofibers. On the other hand, the image verifies that the PAN-CuNP nanofibers were coated with nanoparticles, as individual nanoparticles can be observed as small bumps on the surface of a PAN nanofiber (Figure 3b).
3.2. Elemental Analysis of PAN-CuNP Nanofibers with SEM EDX Spectra

The presence of CuNPs on PAN nanofibers was further investigated using SEM techniques, as shown in Figure 4. As depicted in the figure via SEM elemental composition scattering, it can be observed that CuNPs are scattered atop the surface of PAN nanofibers. Results from EDX analysis, as shown in Figure 5 and Table 1, reinforce that increased molecular weight percentage of Cu can be found in PAN-CuNP nanofibers synthesized from a higher wt.% of CuSO₄.

Figure 4. (a) SEM Elemental Distribution of Pure PAN Nanofibers (b) SEM Elemental Distribution of 5% PAN-CuNP Nanofibers (c) SEM Elemental Distribution of 10% PAN-CuNP Nanofibers (d) SEM Elemental Distribution of 15% PAN-CuNP Nanofibers.

Figure 5. (a) EDX Spectrum of Pure PAN Nanofibers (b) EDX Spectrum of 5% PAN-CuNP Nanofibers (c) EDX Spectrum of 10% PAN-CuNP Nanofibers (d) EDX Spectrum of 15% PAN-CuNP Nanofibers.
It has also been observed that PAN-CuNP nanofibers synthesized from increasingly higher wt.% of CuSO$_4$ have decreased nanofiber diameter (Table 1). This is a direct result of increased charge density from the heightened concentration of CuNPs in the based PAN-DMF solution. The increased charge gradient in the colloidal solution induces stronger elongation forces when acted upon with an electrospinner, thus resulting in decreased nanofiber diameter [77].

**Table 1.** Average Nanofiber Diameter and Average Copper Weight Concentration for PAN-CuNP nanofibers Synthesized from Different wt.% of CuSO$_4$ Over Five Trials.

| Sample Classification       | Average Nanofiber Diameter (nm) | Average Cu Weight Concentration (%) |
|-----------------------------|---------------------------------|-------------------------------------|
| Pure PAN Nanofiber          | 5124                            | 0                                   |
| 5% PAN-CuNP Nanofiber       | 3617                            | 1.38                                |
| 10% PAN-CuNP Nanofiber      | 1398                            | 1.72                                |
| 15% PAN-CuNP Nanofiber      | 552                             | 2.29                                |

### 3.3. Characterization of CuNP Size with TEM and DLS

CuNPs found on PAN were also characterized for their size using HAADF-TEM analysis. An example of this is shown in Figure 6a, which depicts the TEM image of multiple CuNPs. Isolated, non-clustered CuNPs were observed to be scattered in 15% PAN/DMF/CuNP colloidal solution and measured for their size. The CuNPs analyzed using TEM techniques had relatively spherical structures that varied in size and shape. The elemental distribution of copper (Figure 6b) and its subsequent EDX Spectrum (Figure 7) also demonstrates that the particles imaged with the TEM were indeed CuNPs as high intensities of copper were measured in regions that contained the particles. The other elemental distributions of the same TEM image can be found in Figure S9.

**Figure 6.** (a) TEM Image of CuNPs of Various Sizes in 15% PAN/DMF/CuNP Colloidal Solution (b) Elemental Distribution of Copper in TEM Image of 15% PAN/DMF/CuNP Colloidal Solution.

Dynamic Light Scattering was also used to examine size distributions of CuNPs found in 15% PAN/DMF/CuNP colloidal solution. Results from DLS further reinforced the CuNPs diameter measurements obtained using TEM techniques (Figure 8). Larger particle measurements are noted as a possible experimental uncertainty and could have been incidences of clusters of CuNPs being identified together as a singular particle. As all PAN/DMF/CuNP colloidal solutions were mixed at a constant speed for the same amount of time, the variation in CuNPs sizes was presumed to be controlled and similar amongst solutions synthesized from different concentrations of CuSO$_4$ [78,79].
3.4. Antibacterial Efficiency Tests

*Escherichia coli* (K-12 DH5α) was initially used for PAN-CuNP nanofiber antibacterial efficiency tests due to the bacteria’s ubiquitous nature and optimal growth kinetics. As seen in Table 2 and Figure S1, pure PAN nanofiber and bulk Cu disks do not have any antibacterial properties. On the other hand, PAN-CuNP nanofibers synthesized from a higher wt.% of CuSO₄ showed significant antibacterial efficiency, with gradually increasing ZOI Diameter Measurements.
Table 2. Antibacterial Efficiency of PAN-CuNP nanofibers Synthesized from Different wt.% of CuSO$_4$ and Bulk Copper Disks on *E. coli*.

| Bacteria Species      | Sample Classification | Average ZOI Diameter (mm) | StDev (Over 3 Trials) |
|-----------------------|-----------------------|---------------------------|------------------------|
| *E. coli* (K-12 DH5a) | Pure PAN nanofiber    | 0                         | 0                      |
| *E. coli* (K-12 DH5a) | Bulk Cu Disk          | 0                         | 0                      |
| *E. coli* (K-12 DH5a) | 5% PAN-CuNP nanofiber | 7.5                       | 0.01                   |
| *E. coli* (K-12 DH5a) | 10% PAN-CuNP nanofiber| 8.0                       | 0.01                   |
| *E. coli* (K-12 DH5a) | 15% PAN-CuNP nanofiber| 8.6                       | 0.02                   |

PAN-CuNP nanofiber disks were then tested on common disease inducing BSL-2 bacteria with antibiotic resistance for their antibacterial efficiency in comparison to *E. coli*. These six bacteria strains were selected because of their high infectivity and their ubiquitous nature. The key characteristics of these bacteria species and their related diseases are listed below in Table 3.

Table 3. Key Characteristics and Related Diseases of BSL-2 Bacteria Tested in the Present Study.

| Bacterial Species       | Key Characteristics                                                                 | Related Diseases                                           |
|-------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------|
| *S. aureus* (10780)     | Opportunistic pathogen, ubiquitous commensal bacterium, some strains have methicillin resistance (MRSA) or vancomycin resistance (VRSA) | Pneumonia, Cellulitis, Bacteremia, Endocarditis             |
| *S. epidermidis* [82,83]| Opportunistic pathogen, occasional appearance at implant sites, highly resistant to antibiotics | Nosocomial sepsis, Endocarditis, Osteomyelitis, Peritonitis |
| *E. faecalis* (10066)   | Normal flora of gastrointestinal tracts, some strains have vancomycin resistance (VRE) | Urinary tract Infection, endocarditis, Inflammatory Bowel Diseases, Periodontitis |
| *S. agalactiae* (10787) | Colonizes the genital tract of some women, causing vertical transmission             | Neonatal sepsis, meningitis, pneumonia                     |
| *S. pneumoniae* [88,89] | Respiratory pathogen, some strains have antibiotic resistance                        | Pneumonia, Bacteremia, Meningitis, Otitis Media, Sinusitis  |
| *K. pneumoniae* [90,91] | Gram-negative bacterium, respiratory pathogen, urinary tract pathogen, some strains have antibiotic resistance | Pneumonia, Urinary Tract infection, Nosocomial Bacteremia   |

As shown in Table 4 and Figures S2–S7, 15% PAN-CuNP nanofiber disks were generally more effective than their 10% PAN-CuNP nanofiber disk counterparts. Furthermore, it is also important to note that four of these strains (*S. epidermidis, S. agalactiae, E. faecalis, K. pneumoniae*) were completely resistant to ampicillin, a conventional antibiotic used to treat bacterial infections. Moreover, both 10% PAN-CuNP nanofiber and 15% PAN-CuNP nanofibers were more effective than ampicillin disks for every bacteria other than *S. pneumoniae*. PAN-CuNP nanofibers also demonstrated the most antibacterial activity against *S. aureus* (10780) out of these six types of bacteria.

Table 4. Antibacterial Efficiency of PAN-CuNP nanofibers Synthesized from Different wt.% of CuSO$_4$ on Various Bacteria Strains.

| Bacteria Species       | Average Ampicillin ZOI Diameter (mm) | Average 10% PAN-CuNP Nanofiber ZOI Diameter (mm) | Average 15% PAN-CuNP Nanofiber ZOI Diameter (mm) |
|------------------------|--------------------------------------|--------------------------------------------------|-------------------------------------------------|
| *S. aureus* (10780)    | 6.8                                  | 9.3                                              | 9.7                                             |
| *S. epidermidis*       | 0                                    | 6.7                                              | 8.3                                             |
| *E. faecalis* (10066)  | 0                                    | 6.7                                              | 7.1                                             |
| *S. agalactiae* (10787)| 0                                    | 9.3                                              | 9.4                                             |
| *S. pneumoniae*        | 8.3                                  | 6.7                                              | 7.2                                             |
| *K. pneumoniae*        | 0                                    | 7.3                                              | 8.1                                             |
PAN-CuNP nanofiber disks were then placed on six differently genotyped MRSA and VISA strains (MRSA SCCmec type II, MRSA SCCmec type III, MRSA SCCmec type IV, MRSA SCCmec type VT, VISA) and tested for their antibacterial activity. *S. aureus* infections are usually treated with penicillin; in the event where penicillin fails to treat the bacterial infection, methicillin and vancomycin will be used to eliminate the bacteria [80,81,92]. However, mutated strains are difficult to eliminate with conventional antibiotics and are more capable of inducing CAP related infections compared to non-antibiotic resistant *S. aureus* [93]. This is because mutated *S. aureus* strains such as MRSA are known to have a multitude of genotyping characteristics that require varying methods of treatment [94–96].

Therefore, as seen in Table 5, Figures 9 and S8, 15% PAN-CuNP nanofibers were tested for their efficiency on the five aforementioned variations of Methicillin-Resistant *S. aureus* and one strain of Vancomycin-Intermediate *S. aureus*. The data indicates that 15% PAN-CuNP nanofiber disks demonstrate antibacterial activity against MRSA and VISA.

**Table 5.** Antibacterial Efficiency of 15% PAN-CuNP Nanofibers on Various MRSA and VISA Strains.

| Bacteria Species                        | Sample Classification         | Average 15% PAN-CuNP Nanofiber ZOI Diameter (mm) | STDev (Over 3 Trials) |
|----------------------------------------|-------------------------------|-----------------------------------------------|-----------------------|
| Methicillin-Resistant *S. aureus*      | 15% PAN-CuNP nanofiber       | 8.0                                            | 0.09                  |
| (MRSA, 10451)                          |                               |                                                |                       |
| Methicillin-Resistant *S. aureus*      | 15% PAN-CuNP nanofiber       | 7.5                                            | 0.60                  |
| (MRSA SCCmecII, N315)                  |                               |                                                |                       |
| Methicillin-Resistant *S. aureus*      | 15% PAN-CuNP nanofiber       | 9.1                                            | 1.00                  |
| (MRSA SCCmecIII, 33592)                |                               |                                                |                       |
| Methicillin-Resistant *S. aureus*      | 15% PAN-CuNP nanofiber       | 7.0                                            | 0.05                  |
| (MRSA SCCmecIV, IVa)                   |                               |                                                |                       |
| Methicillin-Resistant *S. aureus*      | 15% PAN-CuNP nanofiber       | 8.1                                            | 0.05                  |
| (MRSA SCCmecVT, TSGH17)                |                               |                                                |                       |
| Vancomycin-Intermediate *S. aureus*    | 15% PAN-CuNP nanofiber       | 6.8                                            | 0.05                  |
| (VISA, µ50)                            |                               |                                                |                       |

**Figure 9.** Bar Graph Representation of the Antibacterial Efficiency of 15% PAN-CuNP Nanofibers on Various MRSA and VISA Strains.
4. Discussion

AFM, SEM, TEM, and DLS tests successfully confirmed the formation of CuNPs on scaffolded PAN-CuNP nanofibers.

PAN-CuNP nanofibers synthesized from PAN/DMF/CuNP colloidal solution via electrospinning have shown antibacterial efficacy against various strains of bacteria. Nanofibers created from higher wt.% concentrations CuSO₄ showed higher antibacterial efficacy against bacteria strains. Moreover, PAN-CuNP nanofiber were more effective than pure PAN nanofibers and bulk Cu disks, demonstrating the antibacterial properties of CuNPs. Furthermore, PAN-CuNP nanofiber demonstrated antibacterial activity against Methicillin-Resistant and Vancomycin-Intermediate S. aureus variants, bacteria strains that were otherwise immune to powerful conventional antibiotics. This implies that these nanofibers could become an alternative to these antibiotics when it comes to in vitro applications. 15% PAN-CuNP nanofibers demonstrated antibacterial activity against all 13 strains of bacteria used in this study despite the fact that each pathogen possesses different characteristics.

Conventional antibiotics are usually more expensive and stored under more specific conditions compared to carbon nanofibers coated with CuNPs, meaning that PAN-CuNP nanofibers can be used as a new antibacterial material that is also more cost-effective and easier to store in certain industries or fields of study [97,98]. In the future, PAN-CuNP nanofibers could be engineered or implemented onto high contact surfaces such as masks and medical or surgical equipment like, implants, tubes and catheters [99]. As copper is a trace element in the human body, PAN-CuNP nanofibers should be a safer option for in vivo or in vitro treatment as compared to other metals that are more toxic or harmful [100]. Hence, it would be possible for these nanofibers to eliminate or reduce bacteria upon immediate contact before they enter other organisms, cause irreversible infections, or mutate into antibiotic resistant.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/nano12132139/s1. Figure S1: (a) Pure PAN Nanofiber Disk, (b) Bulk Cu Disk, (c) 5% PAN-CuNP Nanofiber Disk, (d) 10% PAN-CuNP Nanofiber Disk, and (e) 15% PAN-CuNP Nanofiber Disk ZOI Tests on E. coli, with 5 trials each labelled as sections 1–5. Section 6 is a negative control disk while Section 7 is a positive control disk (Ampicillin). Figure S2: (a) 10% PAN-CuNP Nanofiber Disk and (b) 15% PAN-CuNP Nanofiber Disk ZOI Tests on S. aureus (10780). Figure S3: (a) 10% PAN-CuNP Nanofiber Disk and (b) 15% PAN-CuNP Nanofiber Disk ZOI Tests on S. epidermidis. Figure S4: (a) 10% PAN-CuNP Nanofiber Disk and (b) 15% PAN-CuNP Nanofiber Disk ZOI Tests on E. faecalis (10666). Figure S5: (a) 10% PAN-CuNP Nanofiber Disk and (b) 15% PAN-CuNP Nanofiber Disk ZOI Tests on S. agalactiae (10787). Figure S6: (a) 10% PAN-CuNP Nanofiber Disk and (b) 15% PAN-CuNP Nanofiber Disk ZOI Tests on S. pneumoniae. Figure S7: (a) 10% PAN-CuNP Nanofiber Disk and (b) 15% PAN-CuNP Nanofiber Disk ZOI Tests on K. pneumoniae. Figure S8: 15% PAN-CuNP Nanofiber Disk ZOI Tests on (a) MRSA (10451), (b) MRSA SCCmecII (N315), (c) MRSA SCCmecIII (33592), (d) MRSA SCCmecIV (IVa), (e) MRSA SCCmecV7 (TSGH17), and (f) VISA (µ50). Figure S9: (a) HAADF-TEM Image of PAN/DMF/CuNP Colloidal Solution. (b) Copper, (c) Carbon, (d) Oxygen, (e) Sulfur, and (f) Silicon Elemental Distribution in TEM Image of PAN/DMF/CuNP Colloidal Solution. Figure S10: Cu2p XPS Core-Level Spectra of 15% PAN-CuNP Nanofiber Sample. Table S1: Cu2p XPS Atomic Weight Quantification of 15% PAN-CuNP Nanofiber Sample. Figure S11: Homogenized 15% PAN/DMF/CuNP Solution with Dark Green Hue.

Author Contributions: W.B.W.: conceptualization, data curation, formal analysis, investigation, methodology, validation, visualization, writing—original draft & editing. J.C.C.: funding acquisition, project administration, resources, supervision, writing—review & editing. All authors have read and agreed to the published version of the manuscript.

Funding: The authors extend their appreciation to the Taipei American School Upper School Scientific Research Department, the Kaohsiung Chang Gung Memorial Hospital Immunology and Infection Laboratory (Lab 12), and the Feng-Yuan Hospital Common Microbiology Laboratory for funding this research study and providing all aforementioned equipment and materials. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.

Data Availability Statement: The data supporting this study’s findings are available from the corresponding author upon reasonable request.

Acknowledgments: The authors thank Ying-Yan Huang of the Kaohsiung Chang Gung Memorial Hospital Immunology and Infection Laboratory (Lab 12) and Wei-Yao Wang of the Feng-Yuan Hospital Common Microbiology Laboratory for providing resources related antibacterial efficiency tests and access to BSL-2 laboratories. Regarding sample characterization and analysis, the authors extend their gratitude to Sampson Chiang of Materials Analysis Technology Incorporated (MA-tek) for granting access to their TEM and XPS and offering advice on methods related to TEM and XPS sample analysis. The authors further thank Wei-Lung Tseng and Guang-Hong Zheng of the National Sun Yat-Sen University for granting access to their DLS and offering advice on methods related to DLS sample analysis. The authors also thank Sean Tsao of Taipei American School for acquiring resources.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Eames, I.; Tang, J.; Li, Y.; Wilson, P. Airborne transmission of disease in hospitals. J. R. Soc. Interface 2009, 6, S697–S702. [CrossRef]
2. Bahl, P.; Doolan, C.; De Silva, C.; Chughtai, A.A.; Bourouiba, L.; MacIntyre, C.R. Airborne or droplet precautions for health workers treating coronavirus disease 2019? J. Infect. Dis. 2022, 225, 1561–1568. [CrossRef] [PubMed]
3. Yang, S.; Hua, M.; Liu, X.; Du, C.; Pu, L.; Xiang, P.; Wang, L.; Liu, J. Bacterial and fungal co-infections among COVID-19 patients in intensive care unit. Microbes Infect. 2021, 23, 104806. [CrossRef] [PubMed]
4. Liu, L.; Li, Y.; Nielseni, PV.; Wei, J.; Jensen, R.L. Short-range airborne transmission of expiratory droplets between two people. Indoor Air 2017, 27, 452–462. [CrossRef] [PubMed]
5. Rezaei, M.; Netz, R.R. Airborne virus transmission via respiratory droplets: Effects of droplet evaporation and sedimentation. Curr. Opin. Colloid Interface Sci. 2021, 55, 101471. [CrossRef] [PubMed]
6. Guzman, M.I. An overview of the effect of bioaerosol size in coronavirus disease 2019 transmission. Int. J. Health Plan. Manag. 2022, 36, 257–266. [CrossRef]
7. Ehsanifar, M. Airborne aerosols particles and COVID-19 transition. Environ. Res. 2021, 200, 111752. [CrossRef]
8. Aliabadi, A.A.; Rogak, S.N.; Bartlett, K.H.; Green, S.I. Preventing airborne disease transmission: Review of methods for ventilation design in health care facilities. Adv. Prev. Med. 2011, 11, 124064. [CrossRef]
9. Meselson, M. Droplets and aerosols in the transmission of SARS-CoV-2. N. Engl. J. Med. 2020, 382, 2063. [CrossRef]
10. Pepper, I.L.; Gerba, C.P. Aeromicrobiology. In Environmental Microbiology; Elsevier: San Diego, CA, USA, 2015; pp. 89–110.
11. Prina, E.; Ranzani, O.T.; Torres, A. Community-acquired pneumonia. Lancet 2015, 386, 1097–1108. [CrossRef]
12. Pugliese, G.; Lichtenberg, D.A. Nosocomial bacterial pneumonia: An overview. Am. J. Infect. Control 1987, 15, 249–265. [CrossRef]
13. Jean, S.S.; Chang, Y.C.; Lin, W.C.; Lee, W.S.; Hsueh, P.R.; Hsu, C.W. Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia. J. Clin. Med. 2020, 9, 275. [CrossRef]
14. Brown, P.D.; Lerner, S.A. Community-acquired pneumonia. Lancet 1998, 352, 1295–1302. [CrossRef]
15. Musher, D.M.; Thorner, A.R. Community-acquired pneumonia. N. Engl. J. Med. 2014, 371, 1619–1628. [CrossRef] [PubMed]
16. Wunderink, R.G.; Waterer, G.W. Community-acquired pneumonia. N. Engl. J. Med. 2014, 370, 543–551. [CrossRef] [PubMed]
17. Bartlett, J.G.; Mundy, L.M. Community-acquired pneumonia. N. Engl. J. Med. 1995, 333, 1618–1624. [CrossRef]
18. Polyverino, E. Community-acquired pneumonia. Minerva Anestesiol. 2011, 77, 196–211.
19. François, B.; Jafri, H.S.; Chastre, J.; Sánchez-García, M.; Eggimann, P.; Dequin, P.; Huberlanrt, V.; Soria, L.V.; Boulain, T.; Bretonnière, C.; et al. Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): A multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial. Lancet Infect. Dis. 2021, 21, 1313–1323. [CrossRef]
20. Walters, J.; Foley, N.; Molyneux, M. Pus in the thorax: Management of empyema and lung abscess. Anaesth. Crit. Care Pain Med. 2011, 11, 229–233. [CrossRef]
21. World Health Organization. Fact sheet on pneumonia. Wkly. Epidemiol. Rec. 2013, 88, 126–127.
22. Malikzay, H.C.; Giamarellou, H. Community-acquired methicillin-resistant Staphylococcus aureus infections. Int. J. Antimicrob. Agents 2006, 27, 87–96. [CrossRef]
23. Rozenbaum, R.; Sampaio, M.; Batista, G.; Garibaldi, A.; Terra, G.; Souza, M.; Vieira, E.; Silva-Carvalho, M.; Teixeira, L.; Figueiredo, A. The first report in Brazil of severe infection caused by community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA). Braz. J. Med. Biol. Res. 2009, 42, 756–760. [CrossRef] [PubMed]
24. Appelbaum, P. The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 2006, 12, 16–23. [CrossRef] [PubMed]
25. Turner, N.A.; Sharma-Kuinkel, B.K.; Maskarinec, S.A.; Eichenberger, E.M.; Shah, P.P.; Carugati, M.; Holland, T.L.; Fowler, V.G. Methicillin-resistant Staphylococcus aureus: An overview of basic and clinical research. Nat. Rev. Microbiol. 2019, 17, 203–218. [CrossRef] [PubMed]

26. Seif, W.H.; Wunderink, R.G.; Williams, D.J.; Zhi, Y.; Anderson, E.J.; Balk, R.A.; Fakhran, S.S.; Chappell, J.D.; Casimir, G.; Courtney, D.M.; et al. Staphylococcus aureus community-acquired pneumonia: Prevalence, clinical characteristics, and outcomes. Rev. Infect. Dis. 2016, 63, 300–309. [CrossRef]

27. Tashiro, M.; Ciborowski, P.; Klenk, H.D.; Pulverer, G.; Rott, R. Role of Staphylococcus protease in the development of influenza pneumonia. Nature 1987, 325, 536–537. [CrossRef]

28. Taneja, C.; Haque, N.; Oster, G.; Shorr, A.F.; Zilber, S.; Kyan, P.O.; Reyes, K.C.; Moore, C.; Spalding, J.; Kothari, S.; et al. Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia. Am. J. Hosp. Med. 2010, 5, 528–534. [CrossRef]

29. Browne, K.; Chakraborty, S.; Chen, R.; Willcox, M.D.; Black, D.S.; Walsh, W.R.; Kumar, N. A new era of antibiotics: The clinical potential of antimicrobial peptides. Int. J. Mol. Sci. 2020, 21, 7047. [CrossRef]

30. Otto, M. MRSA virulence and spread. Cell. Microbiol. 2012, 14, 1513–1521. [CrossRef]

31. Centers for Disease Control and Prevention (CDC). Severe methicillin-resistant Staphylococcus aureus community-acquired pneumonia associated with influenza–Louisiana and Georgia, December 2006–January 2007. Morb. Mortal. Wkly. Rep. 2007, 56, 325–329.

32. Cilloniz, C.; Dominedò, C.; Gabarrús, A.; García-Vidal, C.; Becerril, J.; Tovar, D.; Moreno, E.; Pericás, J.M.; Vargas, C.R.; Torres, A. Methicillin-susceptible staphylococcus aureus in community-acquired pneumonia: Risk factors and outcomes. J. Infect. 2021, 82, 76–83. [CrossRef] [PubMed]

33. Gardete, S.; Tomasz, A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J. Clin. Investig. 2014, 124, 2836–2840. [CrossRef]

34. Chu, D.K.; Akl, E.A.; Duda, S.; Solo, K.; Yaacoub, S.; Schünemann, H.J.; El-harakeh, A.; Bognanni, A.; Lotfi, T.; Loeb, M.; et al. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: A systematic review and meta-analysis. Lancet 2020, 395, 1973–1987. [CrossRef]

35. Delanghe, L.; Cauwenberghs, E.; Oster, G.; Shorr, A.F.; Zilber, S.; Kyan, P.O.; Reyes, K.C.; Moore, C.; Spalding, J.; Kothari, S.; et al. Clinical and economic outcomes in patients with community-acquired Staphylococcus aureus pneumonia. Am. J. Hosp. Med. 2010, 5, 528–534. [CrossRef]

36. Gillaspy, A.F.; Lee, C.Y.; Sau, S.; Cheung, A.L.; Smeltzer, M.S. Factors affecting the collagen binding capacity of Staphylococcus aureus. Infect. Immun. 1998, 66, 3170–3178. [CrossRef]

37. Risley, A.L.; Loughman, A.; Cywes-Bentley, C.; Foster, T.J.; Lee, J.C. Capsular polysaccharide masks clumping factor A-mediated adherence of Staphylococcus aureus to fibrinogen and platelets. J. Infect. Dis. 2007, 196, 919–927. [CrossRef]

38. Ahmad, M.F.; Wahab, S.; Ahmad, F.A.; Alam, M.I.; Ather, H.; Siddiqua, A.; Ashraf, S.A.; Shafie, M.A.; Khan, M.I.; Beg, R.A. A novel perspective approach to explore pros and cons of face mask in prevention the spread of SARS-CoV-2 and other pathogens. Saudi Pharm. J. SPJ 2021, 29, 121–133. [CrossRef]

39. Li, Y.; Leung, P.; Yao, L.; Song, Q.; Newton, E. Antimicrobial effect of surgical masks coated with nanoparticles. J. Hosp. Infect. 2006, 62, 58–63. [CrossRef]

40. López-Alcalde, J.; Mateos-Mazón, M.; Guevara, M.; Conterno, L.O.; Sola, I.; Nunes, S.C.; Cosp, X.B. Gloves, gowns and masks for reducing the transmission of meticillin-resistant Staphylococcus aureus (MRSA) in the hospital setting. Cochrane Database Syst. Rev. 2015. [CrossRef]

41. Cavanaugh, D.L.; Berry, J.; Yarbrough, S.; Dahners, L.E. Better prophylaxis against surgical site infection with local as well as systemic antibiotics: An in vivo study. J. Bone Jt. Surg. 2009, 91, 1907–1912. [CrossRef]

42. Ulubayram, K.; Calamak, S.; Shahbazi, R.; Eroglu, I. Nanofibers based antibacterial drug design, delivery and applications. Nat. Rev. Microbiol. 2019, 17, 203–218. [CrossRef] [PubMed]

43. Lemraski, E.G.; Jahangirian, H.; Dashti, M.; Khajehali, E.; Sharafinia, S.; Rafiee-Moghaddam, R.; Webster, T.J. Antimicrobial double-layer wound dressing based on chitosan/polyvinyl alcohol/copper: In vitro and in vivo assessment. Int. J. Nanomed. 2021, 16, 223–235. [CrossRef] [PubMed]

44. Persano, L.; Camposeo, A.; Tekmen, C.; Pignanaro, D. Industrial upscaling of electrospinning and applications of polymer nanofibers: A review. Macromol. Mater. Eng. 2013, 298, 504–520. [CrossRef] [PubMed]

45. Gao, Y.; Bach Truong, Y.; Zhi, Y.; Louis Kyratzis, I. Electrospun antibacterial nanofibers: Production, activity, and in vivo applications. J. Appl. Polym. Sci. 2014, 131. [CrossRef]

46. Qiu, Q.; Chen, S.; Zhi, Y.; Yang, Y.; Zhang, H.; Quan, Z.; Qin, X.; Wang, R.; Yu, J. Functional nanofibers embedded into textiles for durable antibacterial properties. Chem. Eng. J. 2020, 384, 123241. [CrossRef]

47. Sharmagl, N.; Buschatz, H. Polyacrylonitrile (PAN) membranes for ultra-and microfiltration. Desalination 2001, 139, 191–198. [CrossRef]
81. Tong, S.Y.; Davis, J.S.; Eichenberger, E.; Holland, T.L.; Fowler, V.G., Jr. Staphylococcus aureus infections: Epidemiology, pathophysiology, clinical manifestations, and management. *Clin. Microbiol. Rev.* **2015**, *28*, 603–661. [CrossRef]

82. Vuong, C.; Otto, M. Staphylococcus epidermidis infections. *Microbes Infect.* **2002**, *4*, 481–489. [CrossRef]

83. Otto, M. Molecular basis of Staphylococcus epidermidis infections. *Semin. Immunopathol.* **2012**, *34*, 301–214. [CrossRef] [PubMed]

84. Beganovic, M.; Luther, M.K.; Rice, L.B.; Arias, C.A.; Rybak, M.J.; LaPlante, K.L. A review of combination antimicrobial therapy for Enterococcus faecalis bloodstream infections and infective endocarditis. *Clin. Infect. Dis.* **2018**, *67*, 303–309. [CrossRef] [PubMed]

85. Rôças, I.N.; Siqueira, J.F., Jr.; Santos, K.R. Association of Enterococcus faecalis with different forms of periradicular diseases. *J. Endod.* **2004**, *30*, 315–320. [CrossRef] [PubMed]

86. Sulovari, A.; Ninomiya, M.J.; Beck, C.A.; Ricciardi, B.F.; Ketonis, A.; Kaplan, N.B.; Soin, S.P.; McDowell, S.M.; Mahmood, B.; et al. Clinical utilization of species-specific immunoassays for identification of Staphylococcus aureus and Streptococcus agalactiae in orthopedic infections. *J. Orthop. Res.* **2021**, *39*, 2141–2150. [CrossRef] [PubMed]

87. Keefe, G.P. Streptococcus agalactiae mastitis: A review. *Can. Vet. J.* **1997**, *38*, 429.

88. Mushler, D.M. Infections caused by Streptococcus pneumoniae: Clinical spectrum, pathogenesis, immunity, and treatment. *Clin. Infect. Dis.* **1992**, *14*, 801–807. [CrossRef]

89. Bogaert, D.; de Groot, R.; Hermans, P. Streptococcus pneumoniae colonisation: The key to pneumococcal disease. *Lancet Infect. Dis.* **2004**, *4*, 144–154. [CrossRef]

90. Paczosa, M.K.; Mecsas, J. Klebsiella pneumoniae: Going on the offense with a strong defense. *Microbiol. Mol. Biol. Rev.* **2016**, *80*, 629–661. [CrossRef]

91. Keynan, Y.; Rubinstein, E. The changing face of Klebsiella pneumoniae infections in the community. *Int. J. Antimicrob. Agents* **2007**, *30*, 385–389. [CrossRef]

92. Bamberger, D.M.; Boyd, S.E. Management of Staphylococcus aureus infections. *Am. Fam. Physician* **2005**, *72*, 2474–2481. [PubMed]

93. Lee, A.S.; De Lencastre, H.; Garau, J.; Kluytmans, J.; Malhotra-Kumar, S.; Peschel, A.; Harbarth, S. Methicillin-resistant Staphylococcus aureus. *Nat. Rev. Dis. Primers* **2018**, *4*, 18033. [CrossRef] [PubMed]

94. Wang, W.Y.; Chiueh, T.S.; Sun, J.R.; Tsao, S.M.; Lu, J.J. Molecular typing and phenotype characterization of methicillin-resistant Staphylococcus aureus isolates from blood in Taiwan. *PLoS ONE* **2012**, *7*, e30394. [CrossRef] [PubMed]

95. Wang, W.Y.; Hsueh, P.R.; Tsao, S.M.; TIST Study Group. Genotyping of methicillin-resistant Staphylococcus aureus isolates causing invasive infections using spa typing and their correlation with antibiotic susceptibility. *Int. J. Antimicrob. Agents* **2022**, *59*, 106525. [CrossRef]

96. Filippini, M.; Masiero, G.; Moschetti, K. Regional consumption of antibiotics: A demand system approach. *Econ. Model.* **2009**, *26*, 1389–1397. [CrossRef]

97. Kumru, O.S.; Joshi, S.B.; Smith, D.E.; Middaugh, C.R.; Prusik, T.; Volkin, D.B. Vaccine instability in the cold chain: Mechanisms, analysis and formulation strategies. *Biologicals* **2014**, *42*, 237–259. [CrossRef] [PubMed]

98. Ye, Z.; Kim, A.; Mottley, C.Y.; Ellis, M.W.; Wall, C.; Esker, A.R.; Nain, A.S.; Behkam, B. Design of Nanofiber Coatings for Mitigation of Microbial Adhesion: Modeling and Application to Medical Catheters. *ACS Appl. Mater. Interfaces* **2018**, *10*, 15477–15486. [CrossRef] [PubMed]

99. Uauy, R.; Olivares, M.; Gonzalez, M. Essentiality of copper in humans. *Am. J. Clin. Nutr.* **1998**, *67*, 952S–959S. [CrossRef] [PubMed]